Cargando…

Effect of additional treatment with EXenatide in patients with an Acute Myocardial Infarction (EXAMI): study protocol for a randomized controlled trial

BACKGROUND: Myocardial infarction causes irreversible loss of cardiomyocytes and may lead to loss of ventricular function, morbidity and mortality. Infarct size is a major prognostic factor and reduction of infarct size has therefore been an important objective of strategies to improve outcomes. In...

Descripción completa

Detalles Bibliográficos
Autores principales:	Scholte, Martijn, Timmers, Leo, Bernink, Flip JP, Denham, Robert N, Beek, Aernout M, Kamp, Otto, Diamant, Michaela, Horrevoets, Anton JG, Niessen, Hans WM, Chen, Weena JY, van Rossum, Albert C, van Royen, Niels, Doevendans, Pieter A, Appelman, Yolande
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2011
Materias:	Study Protocol
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3235971/ https://www.ncbi.nlm.nih.gov/pubmed/22067476 http://dx.doi.org/10.1186/1745-6215-12-240

Ejemplares similares

Effects of exenatide on cardiac function, perfusion, and energetics in type 2 diabetic patients with cardiomyopathy: a randomized controlled trial against insulin glargine
por: Chen, Weena J. Y., et al.
Publicado: (2017)

Therapeutic application of contrast ultrasound in ST elevation myocardial infarction: Role in coronary thrombosis and microvascular obstruction
por: Slikkerveer, Jeroen, et al.
Publicado: (2017)

Cellular and Pharmacological Targets to Induce Coronary Arteriogenesis
por: Hollander, Maurits R., et al.
Publicado: (2014)

Therapeutic application of ultrasound: contrast-enhanced thrombolysis in acute ST-elevation myocardial infarction; the Sonolysis study
por: Slikkerveer, J., et al.
Publicado: (2011)

Quantification of late gadolinium enhanced CMR in viability assessment in chronic ischemic heart disease: a comparison to functional outcome
por: Beek, Aernout M, et al.
Publicado: (2009)

Revascularization strategies for patients with established chronic coronary syndrome
por: Coerkamp, Casper F., et al.
Publicado: (2022)

Relationship between clinical features and the diagnostic value of CMR tissue characterisation in patients with clinically suspected myocarditis
por: Biesbroek, Stefan P, et al.
Publicado: (2015)

The value of cardiac magnetic resonance in the prediction of left ventricular function improvement following acute myocarditis
por: Biesbroek, P Stefan, et al.
Publicado: (2015)

The influence of microvascular injury on T1- and T2*-relaxation times after acute myocardial infarction
por: Robbers, Lourens, et al.
Publicado: (2014)

Pancreatitis Incidence in the Exenatide BID, Exenatide QW, and Exenatide QW Suspension Development Programs: Pooled Analysis of 35 Clinical Trials
por: Vetter, Marion L., et al.
Publicado: (2019)

Exenatide Affects Circulating Cardiovascular Risk Biomarkers Independently of Changes in Body Composition
por: Bunck, Mathijs C., et al.
Publicado: (2010)

Population pharmacokinetics of exenatide
por: Cirincione, Brenda, et al.
Publicado: (2016)

Safety and Efficacy of Once-Weekly Exenatide Compared With Insulin Glargine Titrated to Target in Patients With Type 2 Diabetes Over 84 Weeks
por: Diamant, Michaela, et al.
Publicado: (2012)

Radiofrequency Ablation of the Atherosclerotic Plaque: a Proof of Concept Study in an Atherosclerotic Model
por: Ellenbroek, Guilielmus H.J.M., et al.
Publicado: (2017)

Acute plasma amylase increase after glucagon‐like peptide ‐1 receptor agonist exenatide administration in Type 2 diabetes
por: Smits, M. M., et al.
Publicado: (2017)

CD40 in coronary artery disease: a matter of macrophages?
por: Jansen, Matthijs F., et al.
Publicado: (2016)

Applying the HEART score is safe and saves
por: Appelman, Y., et al.
Publicado: (2022)

Long-acting preparations of exenatide
por: Cai, Yunpeng, et al.
Publicado: (2013)

Bioresorbable scaffolds: everything resolved?
por: Appelman, Yolande
Publicado: (2015)

Changes in remote myocardial tissue after acute myocardial infarction and its relation to cardiac remodeling: A CMR T1 mapping study
por: Biesbroek, P. Stefan, et al.
Publicado: (2017)

Evaluating the systemic right ventricle by CMR: the importance of consistent and reproducible delineation of the cavity
por: Winter, Michiel M, et al.
Publicado: (2008)

Metabolic changes in type 2 diabetes are reflected in peripheral blood cells, revealing aberrant cytotoxicity, a viral signature, and hypoxia inducible factor activity
por: van der Pouw Kraan, Tineke C. T. M., et al.
Publicado: (2015)

The influence of microvascular injury on native T1 and T2* relaxation values after acute myocardial infarction: implications for non-contrast-enhanced infarct assessment
por: Robbers, Lourens F. H. J., et al.
Publicado: (2017)

Effect of renal impairment on the pharmacokinetics of exenatide
por: Linnebjerg, Helle, et al.
Publicado: (2007)

Evolution of Exenatide as a Diabetes Therapeutic
por: Bhavsar, Sunil, et al.
Publicado: (2013)

Variability in and predictors of glycaemic responses after 24 weeks of treatment with exenatide twice daily and exenatide once weekly
por: Shaw, Jonathan E., et al.
Publicado: (2017)

The Diagnostic Value of Clinical Symptoms in Women and Men Presenting with Chest Pain at the Emergency Department, a Prospective Cohort Study
por: van der Meer, Manon G., et al.
Publicado: (2015)

3.0 T cardiovascular magnetic resonance in patients treated with coronary stenting for myocardial infarction: evaluation of short term safety and image quality
por: Nijveldt, Robin, et al.
Publicado: (2007)

Rapid analysis of right ventricular volumes and systolic function using Cardiovascular Magnetic Resonance Imaging
por: Koestner, Simon C, et al.
Publicado: (2009)

Effects of Exenatide on Measures of β-Cell Function After 3 Years in Metformin-Treated Patients With Type 2 Diabetes
por: Bunck, Mathijs C., et al.
Publicado: (2011)

Outcomes in patients with a first episode of chest pain undergoing early coronary CT imaging
por: Siegersma, Klaske R, et al.
Publicado: (2022)

Efficacy and safety of exenatide once‐weekly vs exenatide twice‐daily in Asian patients with type 2 diabetes mellitus
por: Ji, Linong, et al.
Publicado: (2013)

Efficacy and safety of once‐weekly exenatide after switching from twice‐daily exenatide in patients with type 2 diabetes
por: Watanabe, Yuusuke, et al.
Publicado: (2019)

Effect of race on cardiometabolic responses to once-weekly exenatide: insights from the Exenatide Study of Cardiovascular Event Lowering (EXSCEL)
por: Davis, Timothy M. E., et al.
Publicado: (2022)

Exenatide: A New Promising Antidiabetic Agent
por: Chakraborti, C. K.
Publicado: (2010)

The use of exenatide in severely burned pediatric patients
por: Mecott, Gabriel A, et al.
Publicado: (2010)

Efficacy and tolerability of the new autoinjected suspension of exenatide once weekly versus exenatide twice daily in patients with type 2 diabetes
por: Wysham, Carol H., et al.
Publicado: (2017)

Exenatide at mealtimes in type 1 diabetes—no MAG1C with exenatide, or with other glucagon-like peptide-1 receptor agonists
por: Doggrell, Sheila A.
Publicado: (2020)

Acute renal effects of the GLP-1 receptor agonist exenatide in overweight type 2 diabetes patients: a randomised, double-blind, placebo-controlled trial
por: Tonneijck, Lennart, et al.
Publicado: (2016)

In-vivo T1 cardiovascular magnetic resonance study of diffuse myocardial fibrosis in hypertrophic cardiomyopathy
por: Brouwer, Wessel P, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_0j1ads63p321n6imeb725pfblk